Drug Trial Radar · NCT02472795
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jun 1, 2015
Primary completion
Jan 23, 2017
Study completion Feb 28, 2017
Sponsor
- Lead sponsor
- Viatris Innovation GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.
Conditions
- Systemic Lupus Erythematosus
Interventions
Matching placeboDrug
One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
CenerimodDrug
One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT)Time frame: Baseline to end-of-treatment (EOT) (up to 12 weeks)
- Change in Total Lymphocyte Count From Baseline to Each Post-baseline AssessmentTime frame: Baseline, Week 2, Week 4, Week 8, Week 12, end-of-treatment Visit (up to 12 weeks)
Locations
18 sites in 6 countries. Site status is shown where the registry gives one.
Investigator Site
Anniston, Alabama
Investigator Site
Clearwater, Florida
Investigator Site
Minsk, Belarus
Investigator Site
Minsk, Belarus
Investigator Site
Vitebsk, Belarus
Investigator Site
Plovdiv, Bulgaria
Investigator Site
Plovdiv, Bulgaria
Investigator Site
Sofia, Bulgaria
Investigator Site
Tbilisi, Georgia
Investigator Site
Kemerovo, Russia
Investigator Site
Kursk, Russia
Investigator Site
Omsk, Russia
Investigator Site
Orenburg, Russia
Investigator Site
Smolensk, Russia
Investigator Site
Vladimir, Russia
Investigator Site
Vinnytsia, Ukraine
Investigator Site
Vinnytsia, Ukraine
Investigator Site
Zaporizhia, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.